Physician profile
Daniel A Culver
NPI 1154385516
$67,953.86
in general payments reported to CMS, 2019-2025
10 companies · $4,029 in 2025
The $4,029 reported for 2025 was more than what 86% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $18K · 2021: $4,074 · 2022: $617 · 2023: $12K · 2024: $8,319 · 2025: $4,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,982 · Travel and Lodging: $1,945 · Food and Beverage: $542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,803.45 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,981.86 |
| Travel and Lodging | $1,945.21 |
| Food and Beverage | $541.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $41,414.69 | 2019-2025 | Ofev |
| Merck Sharp & Dohme LLC | $7,989.20 | 2024-2025 | |
| Genentech USA, INC. | $6,170.02 | 2019 | |
| Boehringer Ingelheim International Gmbh | $5,611.87 | 2020-2025 | |
| United Therapeutics Corporation | $3,800.00 | 2020 | |
| Celgene Corporation | $2,826.00 | 2023 | |
| Mallinckrodt Enterprises LLC | $118.35 | 2019 | |
| Biogen, INC. | $23.73 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Culver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.